Manuscripts
Showing 1533 manuscripts.
Vicriviroc and peripheral neuropathy: results from AIDS Clinical Trials Group 5211.
Citation
Tzu-min Yeh, Scott Evans, Roy (Trip) Gulick, David B. Clifford. Vicriviroc and peripheral neuropathy: results from AIDS Clinical Trials Group 5211.. HIV Clinical Trials. 2010. 11: 51-8. PMID: 20400411Year
2010
Journal
HIV Clinical Trials
Pre-existing minority drug-resistant HIV-1 variants, adherence, and risk of antiretroviral treatment failure.
Citation
Roger Paredes, Christina M. Lalama, Heather Ribaudo, Bruce R. Schackman, Cecilia M. Shikuma, Francoise Giguel, William A. Meyer, Victoria A. Johnson, Susan A. Fiscus, Richard T. D'Aquila, Roy (Trip) Gulick, Daniel R. Kuritzkes. Pre-existing minority drug-resistant HIV-1 variants, adherence, and risk of antiretroviral treatment failure.. Journal of Infectious Diseases. 2010. 201: 662-71. PMID: 20102271Year
2010
Journal
Journal of Infectious Diseases
Risk factor analyses for immune reconstitution inflammatory syndrome in a randomized study of early vs. deferred ART during an opportunistic infection.
Citation
Philip Grant, Lauren Komarow, Janet Andersen, Irini Sereti, Savita G. Pahwa, Michael M. Lederman, Joseph J. Eron, Ian M. Sanne, William G. Powderly, Evelyn Hogg, Carol Suckow, Andrew R. Zolopa. Risk factor analyses for immune reconstitution inflammatory syndrome in a randomized study of early vs. deferred ART during an opportunistic infection.. Public Library of Science One. 2010. 5: e11416. PMID: 20617176Year
2010
Journal
Public Library of Science One
Early antiretroviral therapy for patients with acute AIDS-related opportunistic infections: a cost-effectiveness analysis of ACTG A5164
Citation
Early antiretroviral therapy for patients with acute AIDS-related opportunistic infections: a cost-effectiveness analysis of ACTG A5164. HIV Clinical Trials. 2010. 11: 248-59. PMID: 21126955Year
2010
Journal
HIV Clinical Trials
Association between systemic inflammation and incident diabetes in HIV-infected patients after initiation of antiretroviral therapy
Citation
Todd T. Brown, Katherine Tassiopoulos, Ronald J. Bosch, Cecilia M. Shikuma, Grace McComsey. Association between systemic inflammation and incident diabetes in HIV-infected patients after initiation of antiretroviral therapy. Diabetes Care. 2010. 33: 2244-9. PMID: 20664016Year
2010
Journal
Diabetes Care
Measurement of antiretroviral drugs in the lungs of HIV-infected patients
Citation
Homer L. Twigg, Carol T Schnizlein Bick, Michael D. Weiden, Lu (Summer) Zheng, L. Joseph Wheat, Richard B. Day, Helen C. Rominger-Grubbs, Ronald G. Collman, Lawrence Fox, Barbara Brizz, Joan Dragavon, Robert W. Coombs, R. Pat Bucy, Fred T. Valentine. Measurement of antiretroviral drugs in the lungs of HIV-infected patients. HIV Therapy. 2010. 4: 247-51. PMID: 20437681Year
2010
Journal
HIV Therapy
Lopinavir protein binding in HIV-1-infected pregnant women
Citation
B M Best, C Hu, D Holland, A Hermes, S K Burchett, J Read, M Mirochnick, E V Capparelli, International Maternal Pediatric Adolescent AIDS Clinical Trials Group (IMPAACT) P1026s Protocol Team, F T Aweeka, A Stek. Lopinavir protein binding in HIV-1-infected pregnant women. HIV Medicine. 2010. 11: 232-8. PMID: 20002783Year
2010
Journal
HIV Medicine
Study
P1026S
Predictors of growth and body composition in HIV-infected children beginning or changing antiretroviral therapy.
Citation
Caroline J. Chantry, Michael Hughes, Carmelita Alvero, Joseph S. Cervia, Janice Hodge, Peggy R. Borum, John ( Jack ) Moye. Predictors of growth and body composition in HIV-infected children beginning or changing antiretroviral therapy.. HIV Medicine. 2010. 11: 573-83. PMID: 20345880Year
2010
Journal
HIV Medicine
Study
P1010
CYP2C19 genetic variants affect nelfinavir pharmacokinetics and virologic response in HIV-1 infected children receiving HAART.
Citation
Akihiko Saitoh, Edmund Capparelli, Francesca Aweeka, Elizabeth Sarles, Kumud K. Singh, Andrea Kovacs, Sandra K. Burchett, Andrew A. Wiznia, Sharon Appelbaum Nachman, Terence Fenton, Stephen A. Spector. CYP2C19 genetic variants affect nelfinavir pharmacokinetics and virologic response in HIV-1 infected children receiving HAART.. Journal of Acquired Immune Deficiency Syndromes. 2010. 54: 285-289. PMID: 19890215Year
2010
Journal
Journal of Acquired Immune Deficiency Syndromes
Identification of ongoing human immunodeficiency virus type 1 (HIV-1) replication in residual viremia during recombinant HIV-1 poxvirus immunizations in patients with clinically undetectable viral loads on durable suppressive HAART
Citation
Carlum Shiu, Coleen K. Cunningham, Thomas C. Greenough, Petronella Muresan, Victor Sanchez Merino, Vincent J. Carey, Brooks Jackson, Carrie Ziemniak, Lawrence Fox, Marvin Eric Belzer, Stuart C. Ray, Katherine Luzuriaga, Deborah Persaud. Identification of ongoing human immunodeficiency virus type 1 (HIV-1) replication in residual viremia during recombinant HIV-1 poxvirus immunizations in patients with clinically undetectable viral loads on durable suppressive HAART. Journal of Virology. 2010. 83: 9731-42. PMID: 19605490Year
2010
Journal
Journal of Virology
Study
P1059